Calcium carbonate

After a major setback in 2023, Amax Pharmaceuticals finally ushered in a brilliant victory in the United States, its signature innovative delayed release Parkinson's disease treatment drug - Crexont, successfully obtained the authoritative approval of the United States Food and Drug Administration (FDA). This unique oral calcium carbonate/levodopa (CD/LD) extended-release formulation opens a new chapter in the treatment of patients with Parkinson's disease with its superior efficacy and convenience, not only significantly extending their "well" period, but also reducing the number of burdensome daily doses to three times, greatly improving patients' quality of life. The FDA accepted Crexont's application after a thorough review and analysis of the detailed Phase III clinical trial data submitted by Amax. In this critical clinical trial of RISE-PD, Crexont stood out for its exceptional performance, providing patients with an additional 30 precious minutes of "good" time per day compared to traditional ready-to-release CD/LD. In addition, its average daily frequency of taking only three times, compared with five times for traditional drugs, undoubtedly brings unprecedented convenience to patients. The successful approval of Crexont is undoubtedly a significant milestone in the treatment of Parkinson's disease. In the face of the large population of patients in the United States - about 1 million people with Parkinson's disease, and about 90,000 new cases each year, the introduction of Crexont has undoubtedly brought unprecedented hope for patients. The co-ceos of Amax Pharmaceuticals, Chirag Patel and Chintu Patel, could not contain their excitement, saying that it is their greatest honor to bring this epoch-making new treatment to Parkinson's disease patients in the United States. At the same time, the company is also confidently planning to bring this innovative treatment to the international market. However, behind the success is often accompanied by unremitting efforts and challenges. Amax had previously been rejected by the FDA because of insufficient safety data on Crexont. This setback did not break them, but inspired them to be more determined and more rigorous. Now, with the successful approval of Crexont, the drug is expected to generate annual sales of up to $300 million to $500 million, further solidifying its leading position in the treatment of Parkinson's disease. It's worth noting that Amax is not alone. Abbott and Newrod Pharmaceuticals, among others, have faced similar regulatory challenges on the road to developing new levodopa preparations. These experiences show that despite the difficulties ahead, pharmaceutical companies are still working hard to find better treatments for Parkinson's disease. Amax's success has undoubtedly set an example for the entire industry, and has brought more treatment options and light of hope to patients with Parkinson's disease.

NES-ZIONA, Israel, Nov. 27, 2023 /PRNewswire/ -- An exclusive initiative by the Israeli biotechnology company Amorphical brings a breakthrough approach to treating a variety of chronic inflammatory and oncological diseases. Scientific Development and Breakthrough Amorphical has developed a pioneering technology to produce amorphous nano-minerals. The unique structure of these amorphous nano-minerals enables the efficient and rapid absorption of essential minerals in the body. Amorphous nano-minerals also possess a unique ability to stimulate healing mechanisms within the target damaged tissues. Amorphous Calcium Carbonate – Amorphical's Revolutionary Leading Product Calcium is a vital mineral for various physiological activities: bone formation, nerve conductivity, muscle function, boosting the immune system, and many other activities. Carbonate is a crucial molecule for maintaining the body's pH balance by neutralizing excess acidity. Treating the Cause for Disease, Not Just the Symptom Modern lifestyle, characterized by stress, unbalanced diet, and an increase in life expectancy, results in a reduced production of bicarbonate, essential for the proper function of the body. Consequently, the elevated tissue acidity impairs the ability to regulate inflammatory processes, ultimately leading to the development of chronic inflammatory as well as oncological diseases. Due to its unique structure and dissolving properties, unlike the crystalline mineral, the amorphous calcium carbonate can directly target inflamed or cancerous tissues. When amorphous carbonate calcium reaches the inflamed tissue, a neutralizing reaction occurs within the acidic environment. The resulting neutral environment does not support the inflammatory processes, leading to the desired healing. Neutralizing the acidic environment is also crucial in treating oncological diseases. Most oncological diseases are characterized by anaerobic respiration of cancer cells, creating an acidic environment within the tumor. This acidic environment supports the rapid division of cancer cells and the development of metastases, while preventing the immune system from attacking and eliminating the cancer cells. Neutralizing the acidic environment in the cancerous tissue by amorphous calcium carbonate inhibits the enhanced metabolic activity of the cancer cells, required for their rapid division. In parallel to the reduction in cancer cell proliferation, the neutralization of the acidic environment within the tumor allows the immune cells to resume their activity, and attack and destroy the cancer cells. To date, this is the sole technology capable of treating and curing a wide range of oncological diseases by transforming the cancerous environment into a healthy environment. Comparison to Current Medications Current medications for chronic inflammatory diseases primarily aim to alleviate symptoms rather than target the disease accelerator, which is the acidic environment within the inflamed tissue. In contrast, amorphous calcium carbonate neutralizes the acidic environment specifically in the inflamed tissue, and thus enables the healing of the inflammation. Conditions Suitable for Treatment by Amorphous Calcium Carbonate The innovative treatment with amorphous calcium carbonate promotes prompt and effective recovery across a variety of diseases: 1. Crohn's Disease, Multiple Sclerosis, Osteoporosis, Arthritis, Pulmonary diseases, and other chronic inflammatory diseases. 2. A wide range of oncological diseases including breast, prostate, colon, liver cancers, and more. 3. The treatment has proven to be highly effective in managing COVID-19. 4. The treatment significantly slows down aging processes and substantially improves the quality of life. Selected Scientific Publications on the Medical Activity of Amorphical's Nano-Amorphous Calcium Carbonate: Lung Cancer: Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity. Cancers (Basel). 2023 Jul 26;15(15):3785 Treatment for COVID-19: Sublingual and Inhaled Amorphous Calcium Carbonate for Hospitalized Patients with SARS-CoV-2: A Phase 1/2 Clinical Study. J Clin Trials. 2023 Vol.13 Iss. 4 No: 1000551 Effect on Mouse Embryos: The effect of amorphous calcium carbonate as a culture media supplement on embryonic development of murine sibling embryos. J Assist Reprod Genet. 2023 Oct;40(10):2409-2418 Additional articles describing the treatment with Amorphical's amorphous nano-minerals are presented on the company's website. For more information, please contact: Noga Nadel Erental - [email protected] Logo -